Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.38 |
| ▸ | PDE1A | P54750 | 1/20 | 0.38 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.38 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAT2A | P31153 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.35 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2861122 | 0.94 | PDE1A (0.39) | RXFP1PDE1APDE1BPDE1CMAPT | |
| SCHEMBL2866691 | 0.91 | PIK3R1 (0.40) | RXFP1P2RX3PDE1APDE1BPDE1C | |
| SCHEMBL2857641 | 0.89 | PDE1B (0.38) | RXFP1PDE1APDE1BPDE1CMAPT | |
| SCHEMBL2862341 | 0.86 | PDE1B (0.40) | RXFP1PDE1APDE1BPDE1CMAPT | |
| SCHEMBL13066568 | 0.85 | HPGD (0.35) | RXFP1MAPTTP53LMNAPOLB | |
| SCHEMBL2865416 | 0.85 | S1PR3 (0.41) | PDE1APDE1BPDE1CMAPTLMNA | |
| SCHEMBL2866734 | 0.85 | MAPT (0.42) | RXFP1P2RX3PDE1APDE1BPDE1C | |
| SCHEMBL2862981 | 0.84 | PLA2G10 (0.39) | PDE1APDE1BPDE1CTP53POLB | |
| SCHEMBL2858941 | 0.84 | GAA (0.38) | PDE1APDE1BPDE1CMAPTTP53 | |
| SCHEMBL2870221 | 0.82 | PDE1B (0.38) | PDE1APDE1BPDE1CTP53POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842701-B2 | Pyrazoloquinolone derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-30 | — | — | US | disclosed |
| US-7842701-B2 | Pyrazoloquinolone derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-30 | — | — | US | disclosed |
| US-20070281963-A1 | Pyrazoloquinolone Derivative And Use Thereof | TAKEDA PHARMACEUTICAL COMPANY (JP) | 2007-12-06 | — | — | US | disclosed |
| US-20070281963-A1 | Pyrazoloquinolone Derivative And Use Thereof | TAKEDA PHARMACEUTICAL COMPANY (JP) | 2007-12-06 | — | — | US | disclosed |
| EP-1719771-A1 | PYRAZOLOQUINOLONE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281963-A1 | Pyrazoloquinolone Derivative And Use Thereof | MAP3K20, MAP4K5, MAP4K3 | RXFP1 1309/4885P2RX3 738/4885PDE1A 3138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.